

Supplementary Table 3. Univariate and multivariate Cox regression analysis for OS in NPC patients

Parameters	Univariate analysis			Multivariate analysis		
	Average survival Time(SE)/Months	95%CI	<i>P</i>	Exp (B)	95%CI	<i>P</i>
SSTR2						
Low expression	62.79(1.56)	(59.74-65.84)	0.137	0.50	(0.32-1.12)	0.106
High expression	65.90(2.88)	(60.26-71.54)				
EGFR						
Low expression	70.09(2.47)	(65.24-74.93)	0.004**	0.46	(0.20-1.06)	0.068
High expression	64.91(2.62)	(59.78-70.04)				
Gender						
Male	63.65(2.34)	(59.06-68.24)	0.051	1.15	(0.61-2.18)	0.670
Female	72.65(3.17)	(66.43-78.86)				
Age						
<=45	75.22(2.78)	(69.76-80.67)	0.015*	0.75	(0.40-1.41)	0.374
>45	63.48(2.04)	(59.48-67.49)				
T stage						
T1 and T2	73.74(1.69)	(70.43-77.05)	0.001*	1.10	(0.61-1.98)	0.745
T3 and T4	61.75(2.86)	(56.15-67.34)				
N stage						
N0	73.78(1.21)	(71.40-76.15)	0.001**	0.00	(0.00-)	0.975
N1/2/3	65.58(2.24)	(61.19-69.96)				
M stage						
M0	69.94(2.27)	(65.50-74.39)	0.001**	0.32	(0.15-0.67)	0.002**
M1	45.84(5.48)	(35.10-56.57)				
Treatment therapy						
CR	67.74(2.58)	(62.70-72.79)	0.001**	5.97	(2.35-15.16)	0.001**
CR and targeted therapy	79.14(2.38)	(74.46-83.81)				

Abbreviations: NPC: nasopharyngeal carcinomas; OS: overall survival; SE, Standard error (SE); Exp(B), Exponentiation of the B coefficient; CI, Confidence interval; SSTR2, Somatostatin receptor 2; EGFR, epidermal growth factor receptor, CR, chemo-radiotherapy.

Note: Analysis of Cox regression, **P*<0.05, ***P*<0.01.